Episode 58: ASM Roundup - Day 1 with Dr Marinka Twilt

Hosts: Dr. Daniel Ennis, Dr. Janet PopeGuest: Dr. Marinka Twilt (Pediatric Rheumatologist, University of Calgary; ASM Program Committee Chair)We’re coming to you almost live from Halifax for Day 1 of the Canadian Rheumatology Association ASM. The day featured key updates across the field, including gaps in pediatric trials, growing recognition of autoinflammatory diseases, and the expanding role of genetics.The SELECT-GCA trial reinforced that upadacitinib is effective for both induction and maintenance of Giant Cell Arteritis (GCA), with high relapse rates after stopping—supporting longer-term treatment. In pediatric ANCA vasculitis, rituximab showed similar efficacy to cyclophosphamide with a safer profile.Sessions on “tough-to-treat RA” highlighted how often non-inflammatory factors drive symptoms, while Clinical Pearls and Medical Mysteries emphasized revisiting diagnoses and the importance of pathology and genetics.The keynote by Dr. Elizabeth Volkman rounded out the day with a focus on holistic care and patient empowerment. Main TakeawaysGCA likely requires longer-term therapy to prevent relapseRituximab is a safe, effective alternative in pediatric ANCA vasculitis“Tough-to-treat RA” often reflects non-inflammatory diseaseReassess when treatments fail—diagnosis evolvesGenetics and pathology are increasingly central to complex casesHolistic care and patient empowerment matter for outcomesWhat to Watch on Day 2New myositis insights, including statin-associated diseasePodium presentations showcasing emerging researchHands-on workshops (including TMJ)Poster tours, with a focus on trainee workThe Great Debate: “Be it resolved that medications should be tapered in patients with inflammatory arthritis in remission.”More highlights coming tomorrow—stay tuned!